Pregabalin: Dose-response relationship in generalized anxiety disorder

Pharmacopsychiatry

Volumn 45, Issue 2, 2012, Pages 51-56

  Boschen, M J ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

anxiety; anxiety disorder; dose response curve; generalized anxiety disorder; pregabalin

Indexed keywords

PREGABALIN;

ANXIETY; ARTICLE; CURVE FITTING; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEAR; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOMATICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TENSION; TREATMENT OUTCOME;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS;

EID: 84858445438     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1291176     Document Type: Article

References (28)

1. th ed. text rev. Washington, DC American Psychiatric Press: 2000
2. Somers J M, Goldner E M, Waraich P et al. Prevalence and incidence studies of anxiety disorders: A systematic review of the literature. Can J Psychiatry: 2006; 51 100 113
3. Barrera T L, Norton P J. Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord: 2009; 23 1086 1090
4. Stein M B, Heimberg R G. Well-being and life satisfaction in generalized anxiety disorder: Comparison to major depressive disorder in a community sample. J Affect Disord: 2004; 79 161 166 (Pubitemid 38340539)
5. Kroenke K, Spitzer R L, Williams JB W et al. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med: 2007; 146 317 325 (Pubitemid 351650592)
6. Jones G N, Ames S C, Jeffries S K et al. Utilization of medical services and quality of life among low-income patients with generalized anxiety disorder attending primary care clinics. Int J Psychiatry Med: 2001; 21 183 198 (Pubitemid 33049662)
7. Boschen M J. Publication trends in individual anxiety disorders: 1980-2005. J Anxiety Disord: 2008; 22 570 575 (Pubitemid 351375355)
8. Boschen M J, Neumann D L, Waters A M. Relapse of successfully treated anxiety and fear: Theoretical issues and recommendations for clinical practice. Aust N Z J Psychiatry: 2009; 43 89 100
9. Yonkers K A, Bruce S E, Dyck I R et al. Chronicity, relapse, and illness-course of panic disorder, social phobia, and generalized anxiety disorder: Findings in men and women from 8 years of follow-up. Depress Anxiety: 2003; 17 173 179 (Pubitemid 36644715)
10. Baldwin D S, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat: 2007; 3 185 191 (Pubitemid 46864058)
11. Boschen M J. Generalized anxiety disorder in adults: Focus on pregabalin. Clin Med Insights: Psychiat: 2011; 4 17 35
12. Czuczwar S J, Patsalos P M. The new generation of GABA enhancers: Potential in the treatment of epilepsy. CNS Drugs: 2001; 15 339 350 (Pubitemid 32487991)
13. 2 ligands at voltage-gated calcium channels. J Clin Psychiat: 2004; 65 460 461
14. 2 ligands: Voltage sensitive calcium channel (VSCC) modulators. J Clin Psychiat: 2004; 65 1033 1034
15. Feltner D E, Crockatt J G, Dubovsky S J et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol: 2003; 23 240 249 (Pubitemid 36807791)
16. Pande A C, Crockatt J G, Feltner D E et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiat: 2003; 160 533 540 (Pubitemid 41094262)
17. Rickels K, Pollack M H, Feltner D E et al. Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiat: 2005; 62 1022 1030 (Pubitemid 41248382)
18. Pohl R B, Feltner D E, Fieve R R et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol: 2005; 25 151 158 (Pubitemid 40395093)
19. Montgomery S A, Tobias K, Zornberg G L et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiat: 2006; 67 771 782 (Pubitemid 43946184)
20. Montgomery S A, Chatamra K, Pauer L et al. Efficacy and safety of pregabalin in elderly people with generalized anxiety disorder. Br J Psychiat: 2008; 193 389 394
21. Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: Results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol: 2009; 24 87 96
22. Feltner D, Wittchen H-U, Kavoussi R et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol: 2008; 23 18 28 (Pubitemid 350294866)
23. Boschen M J. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry: 2011; 56 558 566
24. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder: A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry: 2007; 40 163 168 (Pubitemid 47434876)
25. Lydiard R B, Rickels K, Herman B et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol: 2010; 13 229 241
26. SPSS Inc SPSS for Windows, Release 17.0. Chicago SPSS Inc: 2008
27. Montgomery S A, Kasper S. Pharmacotherapy update: Pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights: Therapeutics: 2010; 2 189 202
28. Frame B, Miller R, Hutmacher M M. Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder. J Pharmacokinet Pharmacodyn: 2009; 36 565 584